← Back to Patent Explorer
US4484923A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for administering immunopotentiator

Assignee: Alza Corp
•
Filing: 1984-01-05
•
Granted: 1984-11-27
•
Expires: 2004-01-05
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention pertains to the administration of an immunopotentiator to activate an immune response. The administration comprises the controlled and continuous administration of the immunopotentiator leading to a high immune response with adequate persistancy, while simultaneously and substantially reducing or eliminating inflammatory reactions usually accompanying depot-type administration.

Inventors

  • 👤 Alfred A. Amkraut
  • 👤 Agusto B. Martins

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-06 13:17
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0002; A61K9/0004; A61K39/00; A61K39/39; Y; Y02; Y02A; Y02A50/00; Y02A50/30

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 161 words
A method for potentiating the immune response of a host, which method consists essentially of administering to a host having an immune system and needing potentiation of its immune response, an immunopotentiating agent that is a member selected from the group consisting of an immunopotentiating lipid, immunopotentiating levamisole, immunopotentiating cord factor, immunopotentiating tilorane, immunopotentiating saponin, immunopotentiators prepared synthetically and derived from the endocrine system, immunopotentiators prepared synthetically and derived from the lymph system and immunopotentiators prepared synthetically and derived from the reticuloendothelial system, and wherein said agent is administered from a therapeutic delivery system that limits the contact of the host with the agent until the agent is released from the system, thereby lessening the incidence of local inflammation, fever and adverse biological response of the host to the agent, which agent is administered at a controlled rate and continously in a therapeutically effective amount of at least one picogram for a prolonged period of time for potentiating the immune response.
Claim 2
Independent Claim 161 words
A method for potentiating the immune response of a host, which method consists essentially of administering to a host having an immune system and needing potentiation of its immune response, an immunopotentiating agent that is a member selected from the group consisting of an immunopotentiating lipid, immunopotentiating levamisole, immunopotentiating cord factor, immunopotentiating tilorane, immunopotentiating saponin, immunopotentiators prepared synthetically and derived from the endocrine system, immunopotentiators prepared synthetically and derived from the lymph system and immunopotentiators prepared synthetically and derived from the reticuloendothelial system, and wherein said agent is administered from a therapeutic delivery system that limits the contact of the host with the agent until the agent is released from the system, thereby lessening the incidence of local inflammation, fever and adverse biological response of the host to the agent, which agent is administered at a controlled rate and continously in a therapeutically effective amount of at least one picogram for a prolonged period of time for potentiating the immune response.
Claim 3
Dependent Claim 30 words
The method for potentiating the immune response of a host according to claim 1, wherein the immunopotentiating agent is present in the therapeutic delivery system with a pharmaceutically acceptable carrier.
Claim 4
Independent Claim 141 words
A method for potentiating the immune response of a host, which method consists essentially of administering to a host having an immune system and needing potentiation of its immune response, an immunopotentiating agent that is a member selected from the group consisting essentially of an immunopotentiating lipopolysaccharide, immunopotentiating protein, immunopotentiating peptide, immunopotentiating peptidoglycan, immunopotentiating glycopeptides, immunopotentiating interferon, immunopotentiating lymphokines, and immunopotentiating muramyl peptide, and wherein said agent is administered from a therapeutic delivery system that limits the contact of the host with the agent until the agent is released from the system, thereby lessening the incidence of local inflammation, fever and adverse biological response of the host to the agent, which agent is administered at a controlled rate and continuously in a therapeutically effective amount of at least one picogram for a prolonged period of time for potentiating the immune response.
Claim 5
Independent Claim 141 words
A method for potentiating the immune response of a host, which method consists essentially of administering to a host having an immune system and needing potentiation of its immune response, an immunopotentiating agent that is a member selected from the group consisting essentially of an immunopotentiating lipopolysaccharide, immunopotentiating protein, immunopotentiating peptide, immunopotentiating peptidoglycan, immunopotentiating glycopeptides, immunopotentiating interferon, immunopotentiating lymphokines, and immunopotentiating muramyl peptide, and wherein said agent is administered from a therapeutic delivery system that limits the contact of the host with the agent until the agent is released from the system, thereby lessening the incidence of local inflammation, fever and adverse biological response of the host to the agent, which agent is administered at a controlled rate and continuously in a therapeutically effective amount of at least one picogram for a prolonged period of time for potentiating the immune response.
Claim 6
Dependent Claim 30 words
The method for potentiating the immune response of a host according to claim 1, wherein the immunopotentiating agent is present in the therapeutic delivery system with a pharmaceutically acceptable carrier.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-11-27 1988-05-28 1988-11-27 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-11-27 1992-05-28 1992-11-27 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-11-27 1996-05-28 1996-11-27 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag